Complications of a severe autoimmune hemolytic anemia crisis: transfusional iron overload and gangrenous cholecystitis. Issue 12 (6th October 2018)

• Record Type: Journal Article
• Authors: Menchetti, Isabella; Lin, Yulia; Cserti‐Gazdewich, Christine; Goldstein, Jenette; Law, Calvin; Lazarus, Alan; Callum, Jeannie L.
• Is Part Of: Transfusion. Volume 58:Issue 12(2018)
• Page Start: 2777
• Page End: 2781
• Publication Date: 2018-10-06
• Subjects: Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; Blood Group Antigens -- Periodicals; Blood Preservation -- Periodicals; Blood Transfusion -- Periodicals; 615
• DOI: 10.1111/trf.14888
• Languages: English
• ISSNs: 0041-1132

Abstract

Abstract : BACKGROUND: Evans syndrome is a rare autoimmune disorder that is defined by the simultaneous or sequential presence of two or more cytopenias without an obvious underlying precipitating cause. Evans syndrome usually follows a chronic relapsing and remitting course and is quite rare, making it difficult to evaluate in clinical studies. CASE REPORT: A 66‐year‐old male patient with a 17‐year history of Evans syndrome presented with fulminant autoimmune hemolytic anemia (AIHA). He presented with a markedly elevated C‐reactive protein (CRP; 46 mg/L [normal, 0‐5 mg/L]) before onset of a decrease in hemoglobin. He required the transfusion of 20 units of red blood cells while awaiting response to aggressive immunosuppressive therapy including high‐dose corticosteroids, intravenous immunoglobin therapy, and rituximab. He achieved a complete hematologic response. RESULTS: His postdischarge course was complicated by acute cholecystitis requiring laparoscopic cholecystectomy. In addition, his transfusional iron overload requiring 16 phlebotomies to reduce his ferritin level from 4933 μg/L to 326 μg/L, with phlebotomies ongoing every 2 weeks to achieve a ferritin level of less than 100 μg/L. CONCLUSION: Neither transfusional iron overload nor acute cholecystitis are well‐recognized complications of a severe episode of AIHA. An elevated CRP has been recently recognized as an important prognostic marker in patients with immune thrombocytopenic purpura and this case suggests a need to evaluate its utility in AIHA.